ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GH Guardant Health Inc

17.98
-0.02 (-0.11%)
Last Updated: 15:54:52
Delayed by 15 minutes
Share Name Share Symbol Market Type
Guardant Health Inc NASDAQ:GH NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.02 -0.11% 17.98 17.97 17.99 18.44 17.91 18.01 187,554 15:54:52

Guardant Health to Report Second Quarter Financial Results on August 5, 2021

13/07/2021 1:05pm

Business Wire


Guardant Health (NASDAQ:GH)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Guardant Health Charts.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2021 after market close on Thursday, August 5, 2021. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening.

Investor Contact: Carrie Mendivil investors@guardanthealth.com

Media Contact: Anna Czene press@guardanthealth.com

Julie Johnson julie.johnson@uncappedcommunications.com

1 Year Guardant Health Chart

1 Year Guardant Health Chart

1 Month Guardant Health Chart

1 Month Guardant Health Chart

Your Recent History

Delayed Upgrade Clock